Two new drugs approved in the last week:
1. sotorasib, a drug for a specific KRAS mutation (G12C) in 2nd line metastatic NSCLC
2. infigratinib, basically a "me too" FGFR inhibitor approved for metastatic cholangiocarcinoma
We all discuss the latest adjuvant CHECKMATE study (nivolumab in urothelial carcinoma) and a recent study of seropositivity in cancer patients following COVID vaccination.
